© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 2, 142-153,
January 15, 2003
© 2003 Oxford University Press
ARTICLE |
Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer
Affiliations of authors: G. Konecny, G. Pauletti, M. Pegram, S. Dandekar, Z. Aguilar, C. Wilson, H.-M. Rong, M. Beryt, D. J. Slamon, Division of Hematology-Oncology, Department of Medicine, and Jonsson Comprehensive Cancer Center, University of California at Los Angeles School of Medicine, Los Angeles; M. Untch, I. Bauerfeind, M. Felber, H. Hepp, Department of Obstetrics and Gynecology, Klinikum Grosshadern, Ludwig Maximilians Universität München, München, Germany; H.-J. Wang, Department of Biomathematics, University of California at Los Angeles School of Medicine; R. Seshadri, Flinders Medical Centre, Flinders University of South Australia, Bedford Park.
Correspondence to: Dennis J. Slamon, M.D., Ph.D., Division of Hematology-Oncology, Department of Medicine, 11–934 Factor Bldg., UCLA School of Medicine, Los Angeles, CA 90095–1678 (e-mail: dslamon{at}mednet.ucla.edu).
Background: HER-2/neu, which encodes a receptor tyrosine kinase, is amplified and overexpressed in 20%–25% of human breast cancers. Such tumors are often resistant to hormone therapy. Despite a general inverse association between HER-2/neu amplification/overexpression and estrogen receptor (ER) and/or progesterone receptor (PR) expression, a fraction of patients are both HER-2/neu- and hormone receptor (HR)-positive. The efficacy of hormone therapy in this group is currently a matter of debate. To better understand the relationship between HER-2/neu positivity and HR expression, we analyzed HER-2/neu, ER, and PR as continuous variables in breast cancer cell lines and two cohorts of primary breast cancer patients. Methods: HER-2/neu and ER/PR expression was analyzed by enzyme-linked immunosorbent assay (ELISA) and enzyme immunoassay (EIA), respectively, in 14 human breast cancer cell lines, some of which had been transfected with the HER-2/neu gene. For the clinical study population, HER-2/neu protein levels were assessed by ELISA (cohort A, n = 665), and HER-2/neu gene copy number was determined using fluorescence in situ hybridization (cohort B, n = 894). ER/PR expression was analyzed by EIA (cohort A) or radioligand binding (cohort B). Associations between HER-2/neu and ER/PR expression were analyzed using Spearman’s rho correlation and the chi-square test, and absolute levels were compared using the Mann–Whitney U test. All statistical tests were two-sided. Results: HR-positive human breast cancer cell lines transfected with the HER-2/neu gene expressed statistically significantly lower levels of ER and PR than parental lines. In the clinical cohorts, levels of HER-2/neu overexpression and gene amplification were inversely correlated with ER/PR levels (Cohort A [n = 112]: for ER, r = –0.34, P<.001; for PR, r = –0.24, P = .010. Cohort B [n = 188]: for ER, r = –0.39, P<.001; for PR, r = –0.26, P<.001). Among patients with HR-positive tumors, HER-2/neu-positive tumors had statistically significantly lower ER/PR levels than HER-2/neu-negative ones (Cohort A: for ER, median = 25 fmol/mg [interquartile range {IQR} = 13–78] versus median = 38.5 fmol/mg [IQR = 17–99] and P = .031; for PR, median = 35 fmol/mg [IQR = 12–119] versus median = 88.5 fmol/mg [IQR = 22–236] and P<.001. Cohort B: for ER, median = 44 fmol/mg [IQR = 13–156] versus median = 92 fmol/mg [IQR = 35–235] and P<.001; for PR, median = 36 fmol/mg [IQR = 13–108] versus median = 84 fmol/mg [IQR = 24–250] and P<.001). Patients with higher levels of HER-2/neu overexpression or amplification had statistically significantly lower levels of ER/PR than patients with lower levels of HER-2/neu overexpression or amplification. Conclusion: Because absolute HR levels are strongly related to response to hormone therapy in primary and advanced breast cancer, reduced ER/PR expression may be one mechanism to explain the relative resistance of HER-2/neu-positive:HR-positive tumors to hormone therapy.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer
- Frédérique Spyratos, Cécile Bouchet, Magali Ferrero-Poüs, Michèle Tubiana-Hulin, and Kamel Hacène
J Natl Cancer Inst 2003 95: 1417-1418.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  M. Arnedos, A. Nerurkar, P. Osin, R. A'Hern, I. E. Smith, and M. Dowsett Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC) Ann. Onc., December 1, 2009; 20(12): 1948 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kaufman, J. R. Mackey, M. R. Clemens, P. P. Bapsy, A. Vaid, A. Wardley, S. Tjulandin, M. Jahn, M. Lehle, A. Feyereislova, et al. Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study J. Clin. Oncol., November 20, 2009; 27(33): 5529 - 5537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Johnston, J. Pippen Jr, X. Pivot, M. Lichinitser, S. Sadeghi, V. Dieras, H. L. Gomez, G. Romieu, A. Manikhas, M. J. Kennedy, et al. Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer J. Clin. Oncol., November 20, 2009; 27(33): 5538 - 5546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Gaudet, M. Campan, J. D. Figueroa, X. R. Yang, J. Lissowska, B. Peplonska, L. A. Brinton, D. L. Rimm, P. W. Laird, M. Garcia-Closas, et al. DNA Hypermethylation of ESR1 and PGR in Breast Cancer: Pathologic and Epidemiologic Associations Cancer Epidemiol. Biomarkers Prev., November 1, 2009; 18(11): 3036 - 3043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Niwinska, M. Murawska, and K. Pogoda Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT) Ann. Onc., October 19, 2009; (2009) mdp407v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Finn, M. F. Press, J. Dering, M. Arbushites, M. Koehler, C. Oliva, L. S. Williams, and A. Di Leo Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer J. Clin. Oncol., August 20, 2009; 27(24): 3908 - 3915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. AHN, C.-C. CHANG, and D. A. TALMAGE Loss of Anti-proliferative Effect of All-trans Retinoic Acid in Advanced Stage of Breast Carcinogenesis Anticancer Res, August 1, 2009; 29(8): 2899 - 2904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-H. Liu, F.-P. Xu, J.-Y. Rao, H.-G. Zhuang, X.-L. Luo, L. Li, D.-L. Luo, F. Zhang, and J. Xu Justification of the Change From 10% to 30% for the Immunohistochemical HER2 Scoring Criterion in Breast Cancer Am J Clin Pathol, July 1, 2009; 132(1): 74 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Reilly Aiming for a Direct Hit: Combining Molecular Imaging with Targeted Cancer Therapy J. Nucl. Med., July 1, 2009; 50(7): 1017 - 1019. [Full Text] [PDF]
|
|
|
|
|
|
M. Dowsett, M. Procter, W. McCaskill-Stevens, E. de Azambuja, U. Dafni, J. Rueschoff, B. Jordan, S. Dolci, M. Abramovitz, O. Stoss, et al. Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial J. Clin. Oncol., June 20, 2009; 27(18): 2962 - 2969. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Corkery, J. Crown, M. Clynes, and N. O'Donovan Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer Ann. Onc., May 1, 2009; 20(5): 862 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine Oncologist, April 1, 2009; 14(4): 320 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sauter, J. Lee, J. M.S. Bartlett, D. J. Slamon, and M. F. Press Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations J. Clin. Oncol., March 10, 2009; 27(8): 1323 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Iverson, C. Gillett, P. Cane, C. D. Santini, T. M. Vess, L. Kam-Morgan, A. Wang, M. Eisenberg, C. M. Rowland, J. J. Hessling, et al. A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens J. Mol. Diagn., March 1, 2009; 11(2): 117 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Di Leo and E. Moretti Anthracyclines: The First Generation of Cytotoxic Targeted Agents? A Possible Dream J. Clin. Oncol., November 1, 2008; 26(31): 5011 - 5013. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Makkat, R. Luypaert, T. Stadnik, C. Bourgain, S. Sourbron, M. Dujardin, J. De Greve, and J. De Mey Deconvolution-based Dynamic Contrast-enhanced MR Imaging of Breast Tumors: Correlation of Tumor Blood Flow with Human Epidermal Growth Factor Receptor 2 Status and Clinicopathologic Findings--Preliminary Results Radiology, November 1, 2008; 249(2): 471 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Yeh, W. A. Whitmire III, and M. Albitar Liquid-Based Fluorescence In Situ Hybridization Assay for Detection of ERBB2 Gene Amplification in Patients with Breast Cancer Clin. Chem., November 1, 2008; 54(11): 1831 - 1839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lemieux, P. J. Goodwin, K. I. Pritchard, K. A. Gelmon, L. J. Bordeleau, T. Duchesne, S. Camden, and C. H. Speers Identification of Cancer Care and Protocol Characteristics Associated With Recruitment in Breast Cancer Clinical Trials J. Clin. Oncol., September 20, 2008; 26(27): 4458 - 4465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Costantini, K. Bateman, K. McLarty, K. A. Vallis, and R. M. Reilly Trastuzumab-Resistant Breast Cancer Cells Remain Sensitive to the Auger Electron-Emitting Radiotherapeutic Agent 111In-NLS-Trastuzumab and Are Radiosensitized by Methotrexate J. Nucl. Med., September 1, 2008; 49(9): 1498 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Willis, N. L. Tran, J. M. Chatigny, N. Charlton, H. Vu, S. A.N. Brown, M. A. Black, W. S. McDonough, S. P. Fortin, J. R. Niska, et al. The Fibroblast Growth Factor-Inducible 14 Receptor Is Highly Expressed in HER2-Positive Breast Tumors and Regulates Breast Cancer Cell Invasive Capacity Mol. Cancer Res., May 1, 2008; 6(5): 725 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Arpino, L. Wiechmann, C. K. Osborne, and R. Schiff Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance Endocr. Rev., April 1, 2008; 29(2): 217 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, D. M. Ikeda, B. Narasimhan, T. A. Longacre, R. J. Bleicher, S. Pal, R. J. Jackman, and S. S. Jeffrey Estrogen Receptor-Negative Invasive Breast Cancer: Imaging Features of Tumors with and without Human Epidermal Growth Factor Receptor Type 2 Overexpression Radiology, February 1, 2008; 246(2): 367 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. De Maeyer, E. Van Limbergen, K. De Nys, P. Moerman, N. Pochet, W. Hendrickx, H. Wildiers, R. Paridaens, A. Smeets, M.-R. Christiaens, et al. Does Estrogen Receptor-Negative/Progesterone Receptor-Positive Breast Carcinoma Exist? J. Clin. Oncol., January 10, 2008; 26(2): 335 - 336. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lopez-Tarruella and R. Schiff The Dynamics of Estrogen Receptor Status in Breast Cancer: Re-shaping the Paradigm Clin. Cancer Res., December 1, 2007; 13(23): 6921 - 6925. [Full Text] [PDF]
|
|
|
|
|
|
D. L. Costantini, C. Chan, Z. Cai, K. A. Vallis, and R. M. Reilly 111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer J. Nucl. Med., August 1, 2007; 48(8): 1357 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Belguise, S. Guo, and G. E. Sonenshein Activation of FOXO3a by the Green Tea Polyphenol Epigallocatechin-3-Gallate Induces Estrogen Receptor {alpha} Expression Reversing Invasive Phenotype of Breast Cancer Cells Cancer Res., June 15, 2007; 67(12): 5763 - 5770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Hegde, D. Rusnak, M. Bertiaux, K. Alligood, J. Strum, R. Gagnon, and T. M. Gilmer Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles Mol. Cancer Ther., May 1, 2007; 6(5): 1629 - 1640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Massarweh and R. Schiff Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities Clin. Cancer Res., April 1, 2007; 13(7): 1950 - 1954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Wolff, M. E. H. Hammond, J. N. Schwartz, K. L. Hagerty, D. C. Allred, R. J. Cote, M. Dowsett, P. L. Fitzgibbons, W. M. Hanna, A. Langer, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer J. Clin. Oncol., January 1, 2007; 25(1): 118 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Massarweh and R. Schiff Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S15 - S24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Ponzone, F Montemurro, F Maggiorotto, C Robba, D Gregori, M. Jacomuzzi, F Kubatzki, D Marenco, A Dominguez, N Biglia, et al. Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer Ann. Onc., November 1, 2006; 17(11): 1631 - 1636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Filardo, C. T. Graeber, J. A. Quinn, M. B. Resnick, D. Giri, R. A. DeLellis, M. M. Steinhoff, and E. Sabo Distribution of GPR30, a Seven Membrane-Spanning Estrogen Receptor, in Primary Breast Cancer and its Association with Clinicopathologic Determinants of Tumor Progression. Clin. Cancer Res., November 1, 2006; 12(21): 6359 - 6366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liang, R. A Brekken, and S. M Hyder Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr. Relat. Cancer, September 1, 2006; 13(3): 905 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Massarweh, C. K. Osborne, S. Jiang, A. E. Wakeling, M. Rimawi, S. K. Mohsin, S. Hilsenbeck, and R. Schiff Mechanisms of Tumor Regression and Resistance to Estrogen Deprivation and Fulvestrant in a Model of Estrogen Receptor-Positive, HER-2/neu-Positive Breast Cancer Cancer Res., August 15, 2006; 66(16): 8266 - 8273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. F. Anderson and R. Matsuno Breast cancer heterogeneity: a mixture of at least two main types? J Natl Cancer Inst, July 19, 2006; 98(14): 948 - 951. [Full Text] [PDF]
|
|
|
|
|
|
H. M. Linden, S. A. Stekhova, J. M. Link, J. R. Gralow, R. B. Livingston, G. K. Ellis, P. H. Petra, L. M. Peterson, E. K. Schubert, L. K. Dunnwald, et al. Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer J. Clin. Oncol., June 20, 2006; 24(18): 2793 - 2799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Subbaramaiah, L. R. Howe, E. R. Port, E. Brogi, J. Fishman, C. H. Liu, T. Hla, C. Hudis, and A. J. Dannenberg HER-2/neu Status Is a Determinant of Mammary Aromatase Activity In vivo: Evidence for a Cyclooxygenase-2-Dependent Mechanism. Cancer Res., May 15, 2006; 66(10): 5504 - 5511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Di Modugno, M. Mottolese, A. Di Benedetto, A. Conidi, F. Novelli, L. Perracchio, I. Venturo, C. Botti, E. Jager, A. Santoni, et al. The Cytoskeleton Regulatory Protein hMena (ENAH) Is Overexpressed in Human Benign Breast Lesions with High Risk of Transformation and Human Epidermal Growth Factor Receptor-2-Positive/Hormonal Receptor-Negative Tumors Clin. Cancer Res., March 1, 2006; 12(5): 1470 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Shin, T. Miller, and C. L. Arteaga ErbB Receptor Signaling and Therapeutic Resistance to Aromatase Inhibitors Clin. Cancer Res., February 1, 2006; 12(3): 1008s - 1012s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Kim, X. Cui, S. G. Hilsenbeck, and A. V. Lee Progesterone Receptor Loss Correlates with Human Epidermal Growth Factor Receptor 2 Overexpression in Estrogen Receptor-Positive Breast Cancer Clin. Cancer Res., February 1, 2006; 12(3): 1013s - 1018s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Fiegl, S. Millinger, G. Goebel, E. Muller-Holzner, C. Marth, P. W. Laird, and M. Widschwendter Breast Cancer DNA Methylation Profiles in Cancer Cells and Tumor Stroma: Association with HER-2/neu Status in Primary Breast Cancer Cancer Res., January 1, 2006; 66(1): 29 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Huang, P. Neven, M. Drijkoningen, R. Paridaens, H. Wildiers, E. Van Limbergen, P. Berteloot, F. Amant, I. Vergote, and M. R. Christiaens Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer Ann. Onc., November 1, 2005; 16(11): 1755 - 1761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dowsett, J. Cuzick, C. Wale, T. Howell, J. Houghton, and M. Baum Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating Study J. Clin. Oncol., October 20, 2005; 23(30): 7512 - 7517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Cui, R. Schiff, G. Arpino, C. K. Osborne, and A. V. Lee Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy J. Clin. Oncol., October 20, 2005; 23(30): 7721 - 7735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Wilson and D. J. Slamon Evolving Understanding of Growth Regulation in Human Breast Cancer: Interactions of the Steroid and Peptide Growth Regulatory Pathways J Natl Cancer Inst, September 7, 2005; 97(17): 1238 - 1239. [Full Text] [PDF]
|
|
|
|
|
|
G. Arpino, H. Weiss, A. V. Lee, R. Schiff, S. De Placido, C. K. Osborne, and R. M. Elledge Estrogen Receptor-Positive, Progesterone Receptor-Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance J Natl Cancer Inst, September 7, 2005; 97(17): 1254 - 1261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Howell and A. M Wardley Overview of the impact of conventional systemic therapies on breast cancer Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S9 - S16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y Zhou, S Eppenberger-Castori, U Eppenberger, and C C Benz The NF{kappa}B pathway and endocrine-resistant breast cancer Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S37 - S46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Burstein and E. P. Winer HER2 or Not HER2: That Is the Question J. Clin. Oncol., June 1, 2005; 23(16): 3656 - 3659. [Full Text] [PDF]
|
|
|
|
 |
|
 H J Huang, P Neven, M Drijkoningen, R Paridaens, H Wildiers, E Van Limbergen, P Berteloot, F Amant, I Vergote, and M R Christiaens Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer J. Clin. Pathol., June 1, 2005; 58(6): 611 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Liu, S. Edgerton, X. Yang, A. Kim, D. Ordonez-Ercan, T. Mason, K. Alvarez, C. McKimmey, N. Liu, and A. Thor Low-Dose Dietary Phytoestrogen Abrogates Tamoxifen-Associated Mammary Tumor Prevention Cancer Res., February 1, 2005; 65(3): 879 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Arpino, S. J. Green, D. C. Allred, D. Lew, S. Martino, C. K. Osborne, and R. M. Elledge HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer: A Southwest Oncology Group Study Clin. Cancer Res., September 1, 2004; 10(17): 5670 - 5676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Pegram, G. E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D. J. Slamon Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer J Natl Cancer Inst, May 19, 2004; 96(10): 739 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ross, J. A. Fletcher, K. J. Bloom, G. P. Linette, J. Stec, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein Mol. Cell. Proteomics, April 1, 2004; 3(4): 379 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Konecny, Y. G. Meng, M. Untch, H.-J. Wang, I. Bauerfeind, M. Epstein, P. Stieber, J.-M. Vernes, J. Gutierrez, K. Hong, et al. Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients Clin. Cancer Res., March 1, 2004; 10(5): 1706 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ferretti, S. Di Cosimo, D. Giannarelli, P. Carlini, P. Papaldo, A. Alimonti, A. Fabi, M. Mandala, M. Milella, E. M. Ruggeri, et al. HER2/neu Expression and Hormonal Therapy in Early Breast Cancer: Can Muddy Waters Become Clear? J. Clin. Oncol., February 1, 2004; 22(3): 568 - 569. [Full Text] [PDF]
|
|
|
|
|
|
G. E. Konecny, C. A. Wilson, and D. J. Slamon Is There a Role for Epidermal Growth Factor Receptor Inhibitors in Breast Cancer Prevention? J Natl Cancer Inst, December 17, 2003; 95(24): 1813 - 1815. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ellis, A. Coop, B. Singh, Y. Tao, A. Llombart-Cussac, F. Janicke, L. Mauriac, E. Quebe-Fehling, H. A. Chaudri-Ross, D. B. Evans, et al. Letrozole Inhibits Tumor Proliferation More Effectively than Tamoxifen Independent of HER1/2 Expression Status Cancer Res., October 1, 2003; 63(19): 6523 - 6531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Spyratos, C. Bouchet, M. Ferrero-Pous, M. Tubiana-Hulin, and K. Hacene Re: Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer J Natl Cancer Inst, September 17, 2003; 95(18): 1417 - 1418. [Full Text] [PDF]
|
|
|
|
|
|
G. Atalay, F. Cardoso, A. Awada, and M. J. Piccart Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer Ann. Onc., September 1, 2003; 14(9): 1346 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark, M. Ayers, W. F. Symmans, L. Pusztai, and K. J. Bloom The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy Oncologist, August 1, 2003; 8(4): 307 - 325. [Abstract] [Full Text] [PDF]
|
|